Senti Biosciences Holdings Inc reports results for the quarter ended June 30 - Earnings Summary

Senti Biosciences Holdings

14/08/2026 22:02

Senti Biosciences Holdings Inc SNTI.OQ reported a quarterly adjusted loss of 41 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -56 cents.  The mean expectation of three analysts for the quarter was for a loss of 26 cents per share. Wall Street expected results to range from -33 cents to -20 cents per share.
Revenue was $17.00 thousand​; analysts expected zero. 
Senti Biosciences Holdings Inc's reported EPS for the quarter was a loss of 41 cents​.
The company reported a quarterly loss of $12.75 million.
Senti Biosciences Holdings Inc shares had fallen by 65.1% this quarter and lost 63.1% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 7.6% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Senti Biosciences Holdings Inc is $12.00, about 96.8% above its last closing price of $0.38
This summary was machine generated from LSEG data August 14 at 09:02 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.26
-0.41
Missed
Mar. 31 2026 
-0.36
-0.36
Met
Dec. 31 2025 
-0.41
-0.53
Missed
Sep. 30 2025 
-0.57
-0.69
Missed